PL2968529T3 - Manufacture of peanut formulations for oral desensitization - Google Patents

Manufacture of peanut formulations for oral desensitization

Info

Publication number
PL2968529T3
PL2968529T3 PL14776121T PL14776121T PL2968529T3 PL 2968529 T3 PL2968529 T3 PL 2968529T3 PL 14776121 T PL14776121 T PL 14776121T PL 14776121 T PL14776121 T PL 14776121T PL 2968529 T3 PL2968529 T3 PL 2968529T3
Authority
PL
Poland
Prior art keywords
manufacture
oral desensitization
peanut
formulations
peanut formulations
Prior art date
Application number
PL14776121T
Other languages
Polish (pl)
Inventor
Bryan Walser
Howard V. Raff
Original Assignee
Aimmune Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51528061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2968529(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aimmune Therapeutics, Inc. filed Critical Aimmune Therapeutics, Inc.
Publication of PL2968529T3 publication Critical patent/PL2968529T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Medical Informatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
PL14776121T 2013-03-14 2014-03-12 Manufacture of peanut formulations for oral desensitization PL2968529T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361784964P 2013-03-14 2013-03-14
EP14776121.7A EP2968529B1 (en) 2013-03-14 2014-03-12 Manufacture of peanut formulations for oral desensitization
PCT/US2014/024401 WO2014159607A1 (en) 2013-03-14 2014-03-12 Manufacture of peanut formulations for oral desensitization

Publications (1)

Publication Number Publication Date
PL2968529T3 true PL2968529T3 (en) 2021-04-19

Family

ID=51528061

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14776121T PL2968529T3 (en) 2013-03-14 2014-03-12 Manufacture of peanut formulations for oral desensitization

Country Status (19)

Country Link
US (5) US9198869B2 (en)
EP (3) EP3998080A1 (en)
JP (3) JP6752140B2 (en)
CN (2) CN109125283A (en)
AU (5) AU2014240404B2 (en)
BR (1) BR112015021756B1 (en)
CA (1) CA2903229A1 (en)
DK (2) DK3482771T3 (en)
ES (2) ES2826224T3 (en)
FI (2) FI3482771T3 (en)
FR (1) FR23C1026I2 (en)
HU (1) HUE051831T2 (en)
MX (1) MX2015010315A (en)
NL (1) NL301236I2 (en)
NO (1) NO2023027I1 (en)
PL (1) PL2968529T3 (en)
PT (1) PT2968529T (en)
SI (1) SI2968529T1 (en)
WO (1) WO2014159607A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2924349B1 (en) 2007-12-03 2010-01-01 Dbv Tech ALLERGEN DISENSIBILITY METHOD
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
CN109125283A (en) * 2013-03-14 2019-01-04 艾慕恩治疗公司 The preparation of peanut preparation for oral desensitization
EP3185900A4 (en) 2014-08-25 2018-05-02 Aimmune Therapeutics, Inc. Egg protein formulations and methods of manufacture thereof
MA41020A (en) 2014-11-25 2017-10-03 Evelo Biosciences Inc PROBIOTIC AND PREBIOTIC COMPOSITIONS, AND THEIR METHODS OF USE FOR MODULATION OF THE MICROBIOME
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
KR20170117562A (en) 2015-02-20 2017-10-23 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Mixed allergen composition and method of use thereof
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
TW201709926A (en) * 2015-04-23 2017-03-16 賽諾菲公司 Glucopyranosyl lipid A and allergen formulations for sublingual administration
US10856567B2 (en) 2016-07-22 2020-12-08 Kari Brown Baby food products containing allergenic proteins and methods of delivering same
WO2018104691A1 (en) * 2016-12-05 2018-06-14 Reacta Biotech Limited Oral food challenge meal formulations
JP2020514306A (en) * 2017-01-13 2020-05-21 アイミューン セラピューティクス，インコーポレイテッド Method for producing nut flour and formulations for oral immunotherapy
AU2017279647B2 (en) 2017-02-15 2022-05-26 Euroimmun Medizinische Labordiagnostika Ag An improved assay for the diagnosis of peanut allergy
WO2019018529A1 (en) 2017-07-18 2019-01-24 Before Brands, Inc. Methods for making mixed allergen compositions
US11369676B2 (en) 2017-11-02 2022-06-28 Société des Produits Nestlé S.A. Methods of oral immunotherapy
GB201718342D0 (en) * 2017-11-06 2017-12-20 Cambridge Allergy Ltd Allergenic protein formulations for immunotherapy
AU2019210146A1 (en) 2018-01-16 2020-09-03 Tel Hashomer Medical Research Infrastructure And Services Ltd. Treatment and prevention of seed allergies
EP3829632A4 (en) 2018-07-27 2022-05-04 Société des Produits Nestlé S.A. ORAL IMMUNOTHERAPY UNIT DOSE DELIVERY SYSTEMS AND METHODS
US12433945B2 (en) 2018-08-16 2025-10-07 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
AU2019401576A1 (en) * 2018-12-17 2021-06-24 Société des Produits Nestlé S.A. Formulations for egg oral immunotherapy, methods of manufacture, and treatments for egg allergy
US12226448B2 (en) 2018-12-20 2025-02-18 Société des Produits Nestlé S.A. Peanut oral immunotherapy dosing schedule for missed doses
AU2020213085A1 (en) 2019-01-23 2021-08-12 Société des Produits Nestlé S.A. Methods for making mixed allergen compositions
CA3137295A1 (en) 2019-05-10 2020-11-19 Aimmune Therapeutics, Inc. Methods for improving the quality of life of a patient with a peanut allergy
MX2022001568A (en) * 2019-08-08 2022-03-02 Evonik Operations Gmbh PROCEDURE FOR PREPARING A SOLID DOSAGE FORM AND A LUBRICANT.
EP4061753A4 (en) * 2019-11-20 2023-12-13 Société des Produits Nestlé S.A. METHOD AND SYSTEMS FOR MANAGING THE DISTRIBUTION AND TREATMENT OF A MEDICINAL PRODUCT FOR ORAL IMMUNOTHERAPY FOR FOOD ALLERGY
KR20220119076A (en) * 2019-12-23 2022-08-26 프로타 테라퓨틱스 피티와이 엘티디 pharmaceutical composition
WO2022003604A1 (en) 2020-07-01 2022-01-06 Société des Produits Nestlé S. A. Determining medical staffing for oral immunotherapy
EP4274609A1 (en) 2021-01-08 2023-11-15 Regeneron Pharmaceuticals, Inc. Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
AU2023253754A1 (en) 2022-04-11 2024-10-17 Alk-Abelló A/S Peanut allergen composition

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3809767A (en) 1969-05-12 1974-05-07 Griffith Laboratories Methods of making vegetable protein concentrates
AU1589492A (en) 1991-03-01 1992-10-06 Warner-Lambert Company Starch-based controlled release compositions
US20120164306A1 (en) * 1993-08-03 2012-06-28 Girsh Leonard S Process for preparing hypoallergenic and reduced fat foods
JP3445593B2 (en) * 1994-09-10 2003-09-08 株式会社林原生物化学研究所 Peptides and their uses
AU2065801A (en) 1999-12-06 2001-06-12 Panacea Pharmaceuticals, Llc Passive desensitization
AU1951001A (en) * 2000-04-06 2001-09-17 Panacea Pharm Llc Microbial delivery system
EP1599185A1 (en) * 2003-02-28 2005-11-30 Alk-Abello A/S Dosage form having a saccharide matrix
EP1734975B1 (en) * 2004-03-19 2015-06-10 Herbs Spring, LLC Herbal therapy for the treatment of food allergy
BRPI0520821A2 (en) 2005-12-28 2009-06-30 Teva Pharma fenofibrate pharmaceutical formulations with improved bioavailability
FR2924349B1 (en) * 2007-12-03 2010-01-01 Dbv Tech ALLERGEN DISENSIBILITY METHOD
BRPI0921507A2 (en) 2008-11-19 2016-01-19 Avantor Performance Mat Inc composition, method of preparation of an excipient, pharmaceutical tablet and method of preparation thereof
US8399519B2 (en) 2008-12-19 2013-03-19 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
US8329208B2 (en) * 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
EP2364690A1 (en) * 2010-02-12 2011-09-14 Centro De Ingenieria Genetica Y Biotecnologia Orally administrable pharmaceutical pellet of epidermal growth factor
JP5800527B2 (en) * 2010-03-30 2015-10-28 日東電工株式会社 Stabilized pharmaceutical composition, stabilized pharmaceutical composition solution preparation, film-form preparation and method for producing film-form preparation
AR081776A1 (en) * 2010-06-30 2012-10-17 Novartis Ag PHARMACEUTICAL COMPOSITIONS INCLUDING 4-AMINO-5-FLUORO-3- LACTATE MONOHIDRATE [6- (4-METHYL-PIPERAZIN-1-IL) -1H-BENCIMIDAZOL-2-IL] -1H-QUINOLIN-2-ONA, PROCESS FOR THE COMPOSITION PRODUCTION
CN101912364B (en) * 2010-08-09 2015-07-15 刘会梅 Ginkgolide B liposome medicinal composition
GB201104537D0 (en) 2011-03-17 2011-05-04 Cambridge Entpr Ltd Treatment for peanut allergy
US20140207105A1 (en) * 2011-08-31 2014-07-24 Perosphere, Inc. Methods for Effectively and Rapidly Desensitizing Allergic Patients
WO2013087119A1 (en) 2011-12-16 2013-06-20 Hal Allergy Holding B.V. Pharmaceutical formulations and the use thereof for the treatment of peanut allergy
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
CN109125283A (en) 2013-03-14 2019-01-04 艾慕恩治疗公司 The preparation of peanut preparation for oral desensitization
EP3185900A4 (en) 2014-08-25 2018-05-02 Aimmune Therapeutics, Inc. Egg protein formulations and methods of manufacture thereof
JP2020514306A (en) 2017-01-13 2020-05-21 アイミューン セラピューティクス，インコーポレイテッド Method for producing nut flour and formulations for oral immunotherapy
US11369676B2 (en) 2017-11-02 2022-06-28 Société des Produits Nestlé S.A. Methods of oral immunotherapy

Also Published As

Publication number Publication date
FIC20230022I1 (en) 2023-07-04
EP3482771B1 (en) 2023-01-18
JP6752140B2 (en) 2020-09-09
ES2826224T3 (en) 2021-05-17
US20200129378A1 (en) 2020-04-30
PT2968529T (en) 2020-11-10
JP2016512537A (en) 2016-04-28
AU2016231523A1 (en) 2016-10-06
BR112015021756A8 (en) 2019-11-19
CN105101994A (en) 2015-11-25
CN109125283A (en) 2019-01-04
BR112015021756B1 (en) 2023-01-10
ES2940686T3 (en) 2023-05-10
US11141352B2 (en) 2021-10-12
MX2015010315A (en) 2016-04-13
HK1217660A1 (en) 2017-01-20
AU2020202685A1 (en) 2020-05-14
AU2020202685B2 (en) 2022-01-20
US9198869B2 (en) 2015-12-01
AU2014240404B2 (en) 2016-07-21
SI2968529T1 (en) 2021-03-31
FR23C1026I1 (en) 2023-10-06
CN105101994B (en) 2018-10-12
NO2023027I1 (en) 2023-07-06
DK2968529T3 (en) 2020-10-12
JP7454519B2 (en) 2024-03-22
EP3998080A1 (en) 2022-05-18
US10449118B2 (en) 2019-10-22
EP3482771A1 (en) 2019-05-15
AU2016231523B2 (en) 2018-05-31
AU2014240404A1 (en) 2015-09-17
AU2022201858A1 (en) 2022-04-07
DK3482771T3 (en) 2023-03-20
JP6891205B2 (en) 2021-06-18
EP2968529A4 (en) 2016-10-05
FR23C1026I2 (en) 2024-07-26
US20180042816A1 (en) 2018-02-15
US20230120350A1 (en) 2023-04-20
US20160030289A1 (en) 2016-02-04
HUE051831T2 (en) 2021-03-29
EP2968529A1 (en) 2016-01-20
AU2018222980A1 (en) 2018-09-20
FI3482771T3 (en) 2023-04-03
CA2903229A1 (en) 2014-10-02
JP2019108357A (en) 2019-07-04
JP2021073321A (en) 2021-05-13
EP2968529B1 (en) 2020-08-05
NL301236I2 (en) 2025-07-31
BR112015021756A2 (en) 2017-07-18
US20140271836A1 (en) 2014-09-18
WO2014159607A1 (en) 2014-10-02
AU2022201858B2 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
SI2968529T1 (en) Manufacture of peanut formulations for oral desensitization
IL274024A (en) Oral compositions
IL245855B (en) Oral formulations of pyrrolydine derivatives
IL240797A0 (en) Oral formulations of deferasirox
GB201401248D0 (en) Method of manufacture
IL243268A0 (en) Head positioning aids for premature infants
ZA201602198B (en) Preparation of hydroxy-benzylbenzene derivatives
ZA201505830B (en) Formulations of organc compounds
IL245700A0 (en) Oral care compositions
PL2967110T3 (en) Chewing gum snacks; and methods of making thereof
LT3071191T (en) SLOW RELEASE SOLID ORAL COMPOSITIONS
GB201305231D0 (en) Method of Manufacture
IL240557A0 (en) Transdermal formulations of laquinimod
GB201305103D0 (en) An oral dosage form
ZA201600408B (en) Formulation of metaxalone
SG11201604136PA (en) Improved formulations for virosomes
TH1501001055A (en) Oral insert
IL240741A0 (en) Oral care compositions
GB201311291D0 (en) Method of manufacture
GB201301262D0 (en) Method of manufacture